Replies to post #33409 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Mpre, I'm not sure where you saw that? The only mention of HER2 I can find in the PR is this: "As part of its portfolio refinement, the company has determined it will not pursue further clinical study of ADXS-HER2 at this time, but remains open to ISTs or licensing opportunities."

And they did not "kill" any ongoing trial. They simply "will not pursue further clinical study at this time."

[blueyedcatch]

Her2 was far off from anything,and was going to be a major cash burn. If the data was`nt staggering enough to bring in a partner for it before they were to start the next phase trial,then Adxs made the right decision,or would you rather them spend shareholder money on it by continuing to go it alone? Not me,I say shelf temporarily until we get our approval for Axal,and if in the meantime a suitor comes along to take it,then wonderful,but Adxs lost nothing,they just made another smart move by prioritizing their balance sheet to increase shareholder value. Going it alone on HER 2,on top of everything else the companies is paying for itself,is too much for the current balance sheet,and it would`ve have caused dilution, to continue it alone. Shareholders got saved with this move,they just don`t see it clearly yet...